

Resource Summary Report

Generated by [NIF](#) on Aug 29, 2026

bcbio-nextgen

RRID:SCR_004316

Type: Tool

Proper Citation

bcbio-nextgen (RRID:SCR_004316)

Resource Information

URL: <https://bcbio-nextgen.readthedocs.org/en/latest/>

Proper Citation: bcbio-nextgen (RRID:SCR_004316)

Description: A python toolkit providing best-practice pipelines for fully automated high throughput sequencing analysis.

Abbreviations: bcbio-nextgen

Resource Type: software resource

Keywords: mapreduce/hadoop, bio.tools

Availability: Free, Available for download, Freely available

Resource Name: bcbio-nextgen

Resource ID: SCR_004316

Alternate IDs: biotools:bcbio-nextgen, OMICS_01121, BioTools:bcbio-nextgen

Alternate URLs: <https://github.com/chapmanb/bcbb/blob/master/nextgen/README.md>, <https://bio.tools/bcbio-nextgen>, <https://bio.tools/bcbio-nextgen>

Record Creation Time: 20220129T080223+0000

Record Last Update: 20260829T182206+0000

Ratings and Alerts

No rating or validation information has been found for bcbio-nextgen.

No alerts have been found for bcbio-nextgen.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 165 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Darlix A, et al. (2026) Distinct molecular profiles characterize the spontaneous growth rate of IDHmt low-grade astrocytomas and oligodendrogliomas. *Neuro-oncology*, 28(4), 911.

Boyle J, et al. (2026) Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometrioid Tumors Associated with High CST2 Expression and a Favorable Prognosis. *Cancer research communications*, 6(1), 224.

Tran B, et al. (2026) Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(14), 2850.

Hazra A, et al. (2026) Transcriptome predictors of second breast events in ductal carcinoma in situ: a case-control study including Black and White women. *Breast cancer research : BCR*, 28(1).

Krishnamachari K, et al. (2026) Improved tumor-only variant calling and mutation burden estimation with VarNet-T. *Nature communications*, 17(1).

Sherif S, et al. (2026) A Three-Gene Interferon Signature Predicts Sustained Complete Remission in Pediatric AML Patients. *Cancers*, 18(9).

Rudich ZD, et al. (2026) Multiple Molecular Pathways to Longevity: Opposing Gene Expression Programs Define Distinct Aging Strategies. *bioRxiv : the preprint server for biology*.

Siu LL, et al. (2025) AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(8), 1449.

Cabug AF, et al. (2025) High expression of interleukin-18 receptor alpha correlates with severe respiratory viral disease and defines T cells with reduced cytotoxic signatures. *Nature communications*, 16(1), 10344.

Bersier L, et al. (2025) Chemotherapy-driven intestinal dysbiosis and indole-3-propionic acid rewire myelopoiesis to promote a metastasis-refractory state. *Nature communications*, 17(1), 832.

Verdu Schlie A, et al. (2025) CDK4 loss-of-function mutations cause microcephaly and short stature. *Genes & development*, 39(9-10), 634.

Zungsontiporn N, et al. (2025) The correlation of HLA-A in Thai EGFR-mutated advanced non-small cell lung cancer, outcome, and tumor microenvironment. *Scientific reports*, 15(1), 30989.

Ansari M, et al. (2025) Whole Genome Sequencing of "Mutation-Negative" Individuals With Cornelia de Lange Syndrome. *Human mutation*, 2025, 4711663.

Kafkas ?, et al. (2025) The application of Large Language Models to the phenotype-based prioritization of causative genes in rare disease patients. *Scientific reports*, 15(1), 15093.

Chia S, et al. (2025) CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. *Cell reports. Medicine*, 6(4), 102053.

Zhang Z, et al. (2025) Ddx21 mutant peptide is an effective neoantigen in prophylactic lung cancer vaccines and activates long-term anti-tumor immunity. *Frontiers in immunology*, 16, 1500417.

Li W, et al. (2025) Screening the human druggable genome identifies ABHD17B as an anti-fibrotic target in hepatic stellate cells. *Nature communications*, 16(1), 2109.

Herbst RS, et al. (2025) Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. *Nature medicine*, 31(6), 1958.

Seo WJ, et al. (2025) Molecular signals associated with intraperitoneal chemotherapy resistance in gastric cancer with peritoneal metastasis through PIPS GC trial integrated translational research. *Scientific reports*, 15(1), 35682.

Kitaba NT, et al. (2025) Immune transcriptomic differences in paediatric patients with SARS-CoV-2 compared to other lower respiratory tract infections. *bioRxiv : the preprint server for biology*.